What's Next for Prenatal Screening?

Review highlights gaps in understanding of fetal DNA in maternal blood that may be limiting prenatal testing

1

Noninvasive prenatal testing screens for fetal genetic abnormalities from maternal blood from about 10 weeks’ gestation, but positive results require invasive confirmation.
2

The review identifies low fetal fraction, difficulty distinguishing fetal from maternal DNA, and differences between placental and fetal genotypes as key limitations.
3

Most circulating cell-free fetal DNA is about 143 base pairs long, but circular, ultrashort, and much longer fragments have also been identified.
4

The mechanisms by which cell-free fetal DNA enters and circulates in maternal blood remain unresolved, and direct evidence for release in apoptotic extracellular vesicles is lacking.
5

The authors call for research on DNA origin and particle association, which could inform fetal DNA enrichment methods and support more reliable diagnostic applications.

1